Safety Concerns Are US FDA's Answer To Question On Regulatory Pathway For Hemp’s Lawful Use
Executive Summary
While not asking Science Board for recommendations on allowing lawful use of hemp in non-drug products, agency officials gave clear indication of current position on the question.
You may also be interested in...
Study Finds Data Scarce Where US FDA Wants To Gauge Hemp Safety – Reproductive Toxicity
First systematic mapping study of safety concerns for consumer use of cannabidiol identifies knowledge gaps for reproductive and developmental toxicity. No traditional, guideline-compliant developmental and reproductive toxicity study was available in the public domain through December 2020.
‘Rope Not Dope’ Still Convince Congress On Hemp?
Failing to maintain key non-intoxicating distinction for hemp could cost US market its future. FDA appointment of senior policy advisor for cannabis could change things.
Heightening Focus On Hemp, Cannabis, US FDA Hires Norman Birenbaum As Public Health Advisor
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.